CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate at the H.C. Wainwright BioConnect Investor Conference, which is taking place May 2, 2023, at the Nasdaq Headquarters in New York City. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Fireside chat date and time: Tuesday, May 2, 2023, 1:30 p.m. ET
Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the panel here.
A webcast of the panel can also be accessed under “Events & Presentations” in the Investors section of Foghorn’s website, www.foghorntx.com, and will be available for up to 30 days.
About Foghorn Therapeutics
Foghorn® Therapeutics Inc. is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. Foghorn is developing multiple product candidates in oncology. For more information about Foghorn, visit our website at www.foghorntx.com, and follow us on Twitter and LinkedIn.
Contact:
Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
This email address is being protected from spambots. You need JavaScript enabled to view it.
Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
This email address is being protected from spambots. You need JavaScript enabled to view it.
Michael Lampe, ScientPR (Media)
This email address is being protected from spambots. You need JavaScript enabled to view it.
Hans Vitzthum, LifeSci Advisors (Investors)
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.86 |
| Daily Change: | 0.06 0.77 |
| Daily Volume: | 76,785 |
| Market Cap: | US$434.890M |
May 22, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
